Target Drugs Choice
A New Choice with Precise Medicine
■ Easier, Non-Invasive, and Repeatable Sampling Method
Generally, when patients have a tumor in the breast, lung, or colon, they undergo imaging examinations. Tissue samples of the tumor are also taken via invasive methods, such as needle biopsy or surgery, to aid in greater diagnostic accuracy. However, these invasive methods are often limited by the number of samples that can be taken, the size of the samples, and organ tissue.
Most human DNA exists within cells and after a cell dies, its DNA is released into the bloodstream and becomes cell-free DNA (cfDNA). Similarly, the DNA of a tumor cell that has died is also released into the bloodstream, thereby becoming circulating tumor DNA (ctDNA). The technique of detecting ctDNA in blood samples is called Liquid biopsy. ctDNA can immediately reveal the current genetic variations in a patient's tumor, which enable more effective monitoring of cancer status and earlier detection of recurrence or new mutations. Liquid biopsies therefore help doctors in assessing treatments and continuous monitoring.
■ First Blood-based Tests Covering All Four Mutation Classes
■ Latest NGS Technology: Detect Low Frequency Alleles with Exceptional Sensitivity and Specificity
Generally, there are 168 billion cfDNA molecules in 4 mL of plasma and about 0.1% ctDNA molecules or 168 million ctDNA molecules from tumor in 4 mL of plasma. With approximately 9 ctDNA molecules EGFR T790M mutation, How do we find 9 molecules in billions of cfDNA molecules? We applied CAncer Personalized Profiling by deep Sequencing (CAPP-Seq), a novel next-generation sequencing-based approach for ultrasensitive ctDNA detection and combined advanced error suppression through molecular and bioinformatics approaches, iDES (integrated digital error suppression), which greatly improve the sensitivity and specificity of the detection of low-frequency alleles in ctDNA.
iDES enables the reduction of errors：Increasing error-free positions from 65% to 98%. Reducing wide error rate ~15 fold
■ Provides a Complete and Accurate Genomic Profile into Different Stages and Types of Cancer
1. Nature Medicine. 2014;20(5):548-554.
2. Science Translational Medicine. 2016;8(364):364ra155
3. Nature Biotechnology. 2016;34(5):547-555.
4. Nature Reviews Cancer. 2017; 17:223-238.
■ SOFIVA Drug+
Patients with solid tumors who:
•are assessed to be suitable for target drugs
•have developed drug resistance
•are unable to provide tissue samples
■ SOFIVA Drug+
Identification of Suitable Target Drugs and Clinical Trial Drugs
For patients who are about to undergo targeted therapy for the first time or a new treatment strategy after recurrence, offering a blood sample for ctDNA analysis can help doctors find suitable target drugs or global clinical trial drugs to serve as the basis for their treatments. Examples are listed in the following table:
◆NCCN guideline recommended genes
◆Global Clinical Trials
*With a regular blood test, SOFIFA Monitor+/SOFIVA Monitor can long-term monitor cancer progression and treatment effectiveness
Step 1：Physician or nurse explains test procedure
Step 2：Sign consent form and provide blood sample
Step 3：Sample delivered to laboratory
Step 4：Using newest illumina® NGS technology
Step 5：The report is completed in 14 working days
*This test can only serve as a reference for professional medical personnel. Please consult your doctor regarding the clinical meaning of the results or any other medical issues.
Validation Study has been published in Top-tier Journals
■ Extremely Sensitive and Specific Quantitation of ctDNA
■ Early Detection of Cancer Relapse
■ iDES Enables the Reduction of Errors
2017 ASCO Clinical Validation
■High Concordance of Tissue with Plasma using SOFIVA Drug+